Showing results (341-350 of 387) with videos related to
Sort By:
Pageof 39
Open Forum Infectious Diseases|March 4, 2015
Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised PatientsRichard Fritz, Nicole Hetzelt, Reinhard Ilk, et al.Nature Communications|April 9, 2020
Gating mechanism of elongating β-ketoacyl-ACP synthasesJeffrey T Mindrebo, Ashay Patel, Woojoo E Kim, et al.The Journal of Infectious Diseases|May 20, 2011
A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humansKlaus K Orlinger, Yvonne Hofmeister, Richard Fritz, et al.Journal of Natural Products|December 28, 2002
Plant-like biosynthetic pathways in bacteria: from benzoic acid to chalconeBradley S Moore, Christian Hertweck, Jörn N Hopke, et al.Vaccine|November 9, 2010
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humansBrian A Crowe, Peter Brühl, Marijan Gerencer, et al.Virology Journal|April 18, 2014
Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID miceChristine Hohenadl, Walter Wodal, Astrid Kerschbaum, et al.Clinical and Vaccine Immunology : CVI|December 26, 2014
An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trialNina Wressnigg, Maikel V W van der Velden, Daniel Portsmouth, et al.Journal of Virology|December 15, 2015
Molecular Basis of the Divergent Immunogenicity of Two Pediatric Tick-Borne Encephalitis Virus VaccinesYvonne Beck, Richard Fritz, Klaus Orlinger, et al.ACS Chemical Biology|April 22, 2015
Formation of a Novel Macrocyclic Alkaloid from the Unnatural Farnesyl Diphosphate Analogue Anilinogeranyl Diphosphate by 5-Epi-Aristolochene SynthaseKathleen A Rising, Charisse M Crenshaw, Hyun Jo Koo, et al.Transfusion|October 11, 2011
Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenzaThomas R Kreil, John K Mc Vey, Laura Shau-Ping Lei, et al.Pageof 39